Insilico Medicine announced it has entered a multi-year research and development collaboration with Servier focused on discovering and developing novel oncology therapies, combining Insilico’s AI-driven drug discovery platform, Pharma.AI, with Servier’s global experience in cancer drug development.
Under the terms of the agreement, Insilico is eligible to receive up to $32 million in upfront and near-term R&D payments. Insilico will lead AI-driven discovery and development efforts to identify and advance drug candidates that meet predefined scientific and development criteria, while Servier will share research and development costs.
If the collaboration yields promising drug candidates, Servier is expected to take the lead on subsequent clinical validation, regulatory interactions, and worldwide commercialization. Insilico described the overall collaboration as valued at up to $888 million over multiple years.
Insilico positioned the deal as an extension of its work in AI-enabled oncology drug discovery, highlighting its internal oncology pipeline, including a potential best-in-class pan-TEAD inhibitor (ISM6331) and a MAT2A inhibitor (ISM3412), both in global, multicenter Phase I clinical trials. The company also said four additional oncology programs have been fully or partially out-licensed to partners, with Phase I trials underway.
The company further pointed to gains in early-stage R&D speed enabled by its AI and automation stack. Insilico said it nominated 20 preclinical candidates from 2021 to 2024, with an average timeline of 12 to 18 months from project initiation to preclinical candidate nomination and typically 60 to 200 molecules synthesized and tested per program—compared with what it described as a traditional early discovery average of about 4.5 years.
Insilico also noted that it was recently listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.
KEY QUOTES:
“This collaboration underscores Servier’s commitment to applying cutting-edge technologies to address unmet medical needs for the benefit of patients and reflects our confidence in Insilico’s internally developed and validated AI platform.”
Christophe Thurieau, Executive Director Research, Servier
“I am excited to see the collaboration—it is yet another strong acknowledgment of our AI capabilities and R&D expertise. As we deepen the integration of generative AI into every stage of the pharma value chain, I believe the future of pharmaceutical superintelligence is never so close, where AI agents could actually make decisions and design experiments, driving a virtuous cycle of faster, smarter, and safer drug development.”
Alex Zhavoronkov, PhD, Founder, CEO and CBO, Insilico Medicine
